Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Nintendo Shares Slide After Earnings Miss Raises Switch 2 Margin Concerns 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
FREDERICK, MD, Dec. 07, 2017 -- BioElectronics Corporation (OTC Pink: BIEL), the maker of advanced wearable consumer pain management medical device ActiPatch, announced today the launch of their “Try and Tell” program in the United States.
The ActiPatch® Musculoskeletal Pain Therapy is a wearable medical device that is FDA cleared for non-prescription use. There is clinical evidence that in the UK, where a similar opioid crisis is unfolding, ActiPatch users reported:
- Reduced opioid pain medication use by 33%
- Reduced other prescription pain medication use by 65%
- Reduced pain level by 57%
- Reduced side-effects from overall pain medication usage
The “Try and Tell” program drove ActiPatch sales abroad and expect to achieve the same results in the United States. This Wall Street Journal award winning program is meant to help consumers gain experience with the technology with the sampling of the 7-Day ActiPatch Trial device. Which in turn, converts consumers at the rate of 83% to the 30 Day ActiPatch device.
To launch the “Try and Tell” program, we are offering consumers a FREE ActiPatch 7-Day Trial at www.tryActiPatch.com with the promo code TRYANDTELL. Our hope is to expose consumers to an alternative to opioids and other analgesics that is user friendly, without side effects, and actually WORKS!
ActiPatch is also happy to announce retail distribution in the United States through ANDA, as a national distributor. “We are pleased to get ActiPatch national distribution through ANDA to retailers; it is a HUGE win for us here in the United States and will be a catalyst for growth,” said Keith Nalepka, VP of Sales and Marketing at BioElectronics Corp.
About BioElectronics Corporation
BioElectronics Corporation is a leader in non-invasive electroceuticals and the maker of an industry leading family of disposable, drug-free, pain therapy devices: ActiPatch® Therapy, over-the-counter treatment for back pain and other musculoskeletal complaints; RecoveryRx® Devices for chronic and post-operative wound care; Allay® Menstrual Pain Therapy. For more information, please visit www.bielcorp.com .
Paul Knopick 940.262.3584 [email protected]
